We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Type May Affect Heart Disease Risk

By LabMedica International staff writers
Posted on 28 Aug 2012
The blood type of an individual may affect their risk of coronary heart disease (CHD) as people with certain blood types are more likely to develop the disease than are others. More...


Studies have indicated that ABO blood group might influence plasma lipid level and recently, several genome-wide association studies found that variants at ABO locus were associated with plasma lipid levels and inflammatory markers that were associated with the CHD risk.
Scientists at the Harvard School of Public Health (Boston, MA, USA) examined data covering nearly 90,000 participants aged from 30 to 75 who were followed for 20 years or more in two large well-known American studies that included a cohort of 62,073 women and a cohort of 27,428 adults.

The proportions of men and women in the studies with various blood types were the same as in the general population, and the scientists were able to control for a number of factors that can affect health and heart disease risk, such as age, gender, race, body mass index, diet, smoking, menopause, and medical history.

The blood type AB is the rarest blood type, it occurs in around 7% of Americans, while type O, the most common, occurs in around 43%. Those with blood type AB had a 23% increased risk for heart disease, those with type B had an 11% increased risk, and those with type A had a 5% increased risk, compared to people with type O.

The mechanisms that cause blood type to affect heart disease risk were not investigated, but evidence from other studies gives some clues. Blood type A is linked to higher levels of low-density lipoprotein (LDL) cholesterol, the "bad" cholesterol that clogs up arteries. Blood type AB is linked to inflammation, which can affect how blood vessels work, and people with blood type O have higher levels of a compound that has a beneficial effect on blood flow and clotting.

Lu Qi, MD, PhD, the senior author of the study, said, "It is important to know your blood type, just as it is good to know your cholesterol and blood pressure levels. If you know you are at higher risk, you can reduce the risk by adopting a healthier lifestyle, such as eating right, exercising, and not smoking." Armed with findings like these, health care providers can tailor treatments more effectively. For instance, patients with blood type A could be advised to reduce cholesterol in their diet to lower their risk of heart disease. The study was published on August 14, 2012, in the journal Arteriosclerosis, Thrombosis and Vascular Biology.

Related Links:
Harvard School of Public Health



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.